Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020)
Atea Pharmaceuticals' (AVIR) quarterly Preferred Stock Liabilities came in at $175.7 million in Q3 2020, up 154.28% year-on-year from $69.1 million in Q4 2019, and little changed quarter-over-quarter from $175.7 million in Q2 2020.
Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Atea Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $175.7 million for Q3 2020.
- On a quarterly basis, Preferred Stock Liabilities rose 154.28% year-over-year to $175.7 million in Q3 2020; TTM through Sep 2020 was $175.7 million, a 154.28% increase from a year earlier, with the FY2019 full-year figure at $69.1 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities steadied at $175.7 million in Q3 2020 per AVIR's latest filing, from $175.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $175.7 million in Q2 2020 and bottomed at $69.1 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 175.75 Mn |
| Jun 30, 2020 | 175.75 Mn |
| Mar 31, 2020 | 69.11 Mn |
| Dec 31, 2019 | 69.11 Mn |
| Sep 30, 2019 | 69.11 Mn |